N-Deshydroxyethyl Dasatinib

• UNSPSC Description:

  N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research[1][2].

• Target Antigen:

  Drug Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Target_Protein-binding_moiety_8.html

• Purity:

  98.58

• Solubility:

  DMSO : 55 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CN=C(NC2=NC(C)=NC(N3CCNCC3)=C2)S1)NC4=C(C)C=CC=C4Cl

• Molecular Weight:

  443.95

• References & Citations:

  [1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108(8):1657-1666.|[2]Thappali SR, et al. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. Arzneimittelforschung. 2012 Dec;62(12):624-30.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  910297-51-7